Biocodex led the round, which will fund the start of clinical studies for Maat's microbiome-based dysbiosis treatment this summer.
France-based microbome therapy developer Maat Pharma has raised €10m ($11m) in series A capital from investors including pharmaceutical company Biocodex.
CM-CIC Innovation led the funding, secured ‘within the context of Maat’s series A round’, with participation by venture capital firm Seventure Partners and French agricultural research institute Inra.
The capital will support the commencement of clinical studies for a drug candidate that will treat dysbiosis, a microbial imbalance which can follow the treatment of diseases like leukaemia, in summer this…
